Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Pd1 Immune Checkpoint Blockades

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Not Applicable (1)

Trial Status

Completed1
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT05123287Unknown

A Perspective, Self-control Study on the Progression of Carotid Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up

NCT03072342Not ApplicableCompleted

PERIODONTITIS AND VASCULAR DYSFUNCTION

Showing all 2 trials

Research Network

Common Treatments

  • Pd1 Immune Checkpoint Blockades1
  • Control Periodontal Treatment1
  • Intensive Periodontal Treatment1

Active Sponsors

  • University College, London1
  • Second Affiliated Hospital, Zhejiang University, School of Medicine1

Top Investigators

Related Conditions

  • Plaque Atherosclerotic1
  • Carotid Artery Plaque1
  • Immune Checkpoint Inhibitors1
  • Periodontitis1
  • Programmed Cell Death Protein 1 Inhibitor1

Activity Timeline